Insider Selling: Bruker (NASDAQ:BRKR) Director Sells 6,233 Shares of Stock

Bruker Corporation (NASDAQ:BRKR) Director John Ornell sold 6,233 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the sale, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bruker Trading Up 2.1%

Shares of NASDAQ BRKR traded up $0.85 during midday trading on Monday, hitting $40.78. The stock had a trading volume of 1,929,850 shares, compared to its average volume of 2,835,246. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64. The company has a market capitalization of $6.20 billion, a price-to-earnings ratio of 78.42, a PEG ratio of 5.31 and a beta of 1.26. The company has a fifty day moving average price of $35.02 and a 200 day moving average price of $37.08.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.33 by $0.12. The firm had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s payout ratio is presently -125.00%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on BRKR shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Barclays upped their target price on Bruker from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Citigroup dropped their target price on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, August 4th. TD Cowen upped their price target on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a report on Tuesday, November 4th. Finally, Wells Fargo & Company lowered their price objective on shares of Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $48.30.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently modified their holdings of the stock. Orbis Allan Gray Ltd acquired a new stake in shares of Bruker in the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC increased its holdings in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in Bruker during the second quarter valued at approximately $62,032,000. Norges Bank bought a new position in Bruker during the 2nd quarter worth approximately $44,459,000. Finally, Sculptor Capital LP grew its position in shares of Bruker by 51.6% in the 1st quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock worth $108,459,000 after acquiring an additional 884,423 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.